R M Eglen

Analysis of concentration-response relationships by seemingly unrelated nonlinear regression (SUNR) technique.

E Leung, S Michelson, C Villarubia, 1992, Journal of pharmacological and toxicological methods.

Electrophysiological and antiarrhythmic effects of the atrial selective 5-HT(4) receptor antagonist RS-100302 in experimental atrial flutter and fibrillation.

R M Eglen, A. Ford, R. Eglen, 1999, Circulation.

Characteristics of 5‐HT3 binding sites in NG108‐15, NCB‐20 neuroblastoma cells and rat cerebral cortex using [3H]‐quipazine and [3H]‐GR65630 binding

R M Eglen, E. Wong, N. Sharif, 1991, British journal of pharmacology.

2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists.

R M Eglen, R. Eglen, D. Bonhaus, 1993, Journal of medicinal chemistry.

Muscarinic receptors and gastrointestinal tract smooth muscle function.

R M Eglen, R. Eglen, Richard M. Eglen, 2001, Life sciences.

RS‐127445: a selective, high affinity, orally bioavailable 5‐HT2B receptor antagonist

R M Eglen, G. Martin, A. Webber, 1999, British journal of pharmacology.

A comparison of the potential role of the tetrodotoxin-insensitive sodium channels, PN3/SNS and NaN/SNS2, in rat models of chronic pain.

R M Eglen, J C Hunter, R. Eglen, 1999, Proceedings of the National Academy of Sciences of the United States of America.

7TM receptors: the splicing on the cake.

R M Eglen, G. Martin, Gavin Kilpatrick, 1999, Trends in pharmacological sciences.

Effects of muscarinic M2 and M3 receptor stimulation and antagonism on responses to isoprenaline of guinea‐pig trachea in vitro

R M Eglen, R. Eglen, N Watson, 1994, British journal of pharmacology.